Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Am Surg ; 89(4): 902-906, 2023 Apr.
Article in English | MEDLINE | ID: mdl-34962166

ABSTRACT

BACKGROUND: Breast reconstruction (BR) has documented psychological benefits following mastectomy. Yet, racial/ethnic minority groups have lower reported rates of BR. We sought to evaluate the rate, type, and outcome of BR in a racially and ethnically diverse population within a safety-net hospital system. METHODS: All patients who underwent mastectomy between October 2015 and July 2019 at Harbor-UCLA Medical Center were retrospectively examined. Rates and type of BR were analyzed according to patient characteristics (race/ethnicity, age, and body mass index), smoking status, cancer stage, and presence of diabetes mellitus. Breast reconstruction outcomes were also assessed. RESULTS: Of the 259 patients that underwent mastectomy, 87 (33.6%) received BR. Immediate BR was performed in 79 (30.5%) patients and delayed BR in 8 (3.1%). Of the 79 patients with immediate BR, 58 (73.4%) received implant-based BR and 21 (26.5%) autologous tissue. The BR failure rate was 10%, all implant-based. Increasing age and smoking negatively impacted BR rates. Black (P =.331) and Hispanic (P =.132) ethnicity were not independent predictors of decreased breast reconstruction. CONCLUSION: This study demonstrated that the rate, type, and quality of BR in this integrated safety-net hospital within a diverse population are comparable to national rates. When made available, historically underrepresented minority patients of Black and Hispanic ethnicity utilize BR.


Subject(s)
Breast Neoplasms , Mammaplasty , Humans , Female , Mastectomy , Ethnicity , Retrospective Studies , Breast Neoplasms/surgery , Safety-net Providers , Minority Groups
2.
J Invest Dermatol ; 127(11): 2645-55, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17554369

ABSTRACT

Abnormal wound healing encompasses a wide spectrum, from chronic wounds to hypertrophic scars. Both conditions are associated with an abnormal cytokine profile in the wound bed. In this study, we sought to understand the dynamic relationships between myofibroblast differentiation and mechanical performance of the collagen matrix under tissue growth factor-beta (TGF-beta) and tumor necrosis factor-alpha (TNF-alpha) stimulation. We found TGF-beta increased alpha-smooth muscle actin (alpha-SMA) and TNF-alpha alone decreased the basal alpha-SMA expression. When TGF-beta1 and TNF-alpha were both added, the alpha-SMA expression was suppressed below the baseline. Real-time PCR showed that TNF-alpha suppresses TGF-beta1-induced myofibroblast (fibroproliferative) phenotypic genes, for example, alpha-SMA, collagen type 1A, and fibronectin at the mRNA level. TNF-alpha suppresses TGF-beta1-induced gene expression by affecting its mRNA stability. Our results further showed that TNF-alpha inhibits TGF-beta1-induced Smad-3 phosphorylation via Jun N-terminal kinase signaling. Mechanical testing showed that TNF-alpha decreases the stiffness and contraction of the lattices after 5 days in culture. We proposed that changes in alpha-SMA, collagen, and fibronectin expression result in decreased contraction and stiffness of collagen matrices. Therefore, the balance of cytokines in a wound defines the mechanical properties of the extracellular matrix and optimal wound healing.


Subject(s)
Actins/metabolism , Dermis/metabolism , Fibroblasts/metabolism , Tumor Necrosis Factor-alpha/physiology , Wound Healing/physiology , Actins/genetics , Cells, Cultured , Chronic Disease , Cicatrix, Hypertrophic/metabolism , Cicatrix, Hypertrophic/pathology , Collagen Type I/genetics , Collagen Type I/metabolism , Dermis/cytology , Fibroblasts/cytology , Fibronectins/genetics , Fibronectins/metabolism , Humans , Mitogen-Activated Protein Kinase Kinases/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Signal Transduction/physiology , Smad3 Protein/metabolism , Transforming Growth Factor beta1/pharmacology , Transforming Growth Factor beta1/physiology , Wounds and Injuries/metabolism , Wounds and Injuries/pathology
SELECTION OF CITATIONS
SEARCH DETAIL